Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.6B |
| 2 |
Broadcom
AVGO
|
+$1.11B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$882M |
| 4 |
JPMorgan Chase
JPM
|
+$628M |
| 5 |
Tesla
TSLA
|
+$594M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.54B |
| 2 |
Visa
V
|
+$1.39B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.13B |
| 4 |
Amazon
AMZN
|
+$771M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$575M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 45.6% |
| 2 | Technology | 19.83% |
| 3 | Financials | 7.37% |
| 4 | Consumer Discretionary | 6.6% |
| 5 | Communication Services | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3401
Amylyx Pharmaceuticals
AMLX
$3.49B
| $835K | ﹤0.01% |
130,274
-7,131
| -5% | -$34.7K |
2022 Q1
13 quarters
|
|
3402
Liberty Latin America Class A
LILA
$1.73B
| $834K | ﹤0.01% |
201,243
+109,322
| +119% | +$396K |
2015 Q3
39 quarters
|
|
3403
Wabash National
WNC
$570M
| $832K | ﹤0.01% |
78,264
-31,003
| -28% | -$298K |
2013 Q2
48 quarters
|
|
|
NUTX
3404
Nutex Health
NUTX
$1.54B
| $831K | ﹤0.01% |
+6,678
| New | +$863K |
2025 Q2
0 quarters
|
|
|
FSUN
3405
FirstSun Capital Bancorp
FSUN
$1.73B
| $831K | ﹤0.01% |
23,914
+13,497
| +130% | +$473K |
2024 Q4
2 quarters
|
|
3406
Klaviyo
KVYO
$4.75B
| $828K | ﹤0.01% |
24,657
-7,915
| -24% | -$251K |
2024 Q1
5 quarters
|
|
3407
CALL
L3Harris
LHX
$44.1B
| $828K | ﹤0.01% |
+3,300
| New | +$758K |
2025 Q2
0 quarters
|
|
|
EHAB
3408
DELISTED
Enhabit
EHAB
| $827K | ﹤0.01% |
85,744
+32,202
| +60% | +$297K |
2022 Q3
11 quarters
|
|
3409
JELD-WEN Holding
JELD
$153M
| $826K | ﹤0.01% |
210,688
+53,258
| +34% | +$237K |
2017 Q2
32 quarters
|
|
|
NUVL
3410
CALL
DELISTED
Nuvalent
NUVL
| $824K | ﹤0.01% |
+10,800
| New | +$790K |
2025 Q2
0 quarters
|
|
3411
Ardmore Shipping
ASC
$790M
| $821K | ﹤0.01% |
85,503
+35,053
| +69% | +$338K |
2016 Q3
35 quarters
|
|
3412
Toyota
TM
$218B
| $820K | ﹤0.01% |
4,763
+1,884
| +65% | +$341K |
2013 Q2
48 quarters
|
|
3413
Zumiez
ZUMZ
$210M
| $820K | ﹤0.01% |
61,863
+17,314
| +39% | +$219K |
2013 Q2
48 quarters
|
|
3414
Bank7 Corp
BSVN
$531M
| $820K | ﹤0.01% |
19,604
+5,579
| +40% | +$212K |
2018 Q3
27 quarters
|
|
|
BRY
3415
DELISTED
Berry Corp
BRY
| $820K | ﹤0.01% |
296,024
+75,033
| +34% | +$200K |
2018 Q3
27 quarters
|
|
3416
EVgo
EVGO
$191M
| $819K | ﹤0.01% |
224,401
+62,277
| +38% | +$213K |
2022 Q1
13 quarters
|
|
|
OLP
3417
One Liberty Properties
OLP
$480M
| $816K | ﹤0.01% |
34,211
+14,705
| +75% | +$359K |
2013 Q2
48 quarters
|
|
|
NLOP
3418
Net Lease Office Properties
NLOP
$142M
| $815K | ﹤0.01% |
25,024
+9,633
| +63% | +$295K |
2023 Q4
6 quarters
|
|
3419
United States Antimony
UAMY
$591M
| $809K | ﹤0.01% |
+371,214
| New | +$1.05M |
2025 Q2
0 quarters
|
|
|
RAPP
3420
Rapport Therapeutics
RAPP
$1.54B
| $808K | ﹤0.01% |
71,108
+8,412
| +13% | +$89.3K |
2024 Q2
4 quarters
|
|
3421
America's Car Mart
CRMT
$8.2M
| $808K | ﹤0.01% |
14,427
-12,282
| -46% | -$608K |
2016 Q2
36 quarters
|
|
3422
CALL
CRH
CRH
$55B
| $808K | ﹤0.01% |
8,800
+800
| +10% | +$73K |
2025 Q1
1 quarter
|
|
|
SLSN
3423
Solesence Inc
SLSN
$57.2M
| $807K | ﹤0.01% |
+185,148
| New | +$650K |
2025 Q2
0 quarters
|
|
3424
Preformed Line Products
PLPC
$2.03B
| $806K | ﹤0.01% |
5,045
+2,048
| +68% | +$292K |
2017 Q1
33 quarters
|
|
|
SRTA
3425
Strata Critical Medical Inc
SRTA
$426M
| $804K | ﹤0.01% |
199,458
+47,981
| +32% | +$156K |
2022 Q1
13 quarters
|
|
Similar funds
Barclays's Q2 2025 Portfolio in Review
As of Q2 2025, Barclays held 5,681 positions worth $436B, up 24% from $353B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2025 filing shows 461 new, 2,914 increased, 1,345 reduced and 463 closed positions. Its largest new stake was iShares MBS ETF: 4,310,047 shares worth $405M. The largest sale was Honeywell, an estimated $1.54B.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 41% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2025 buy was iShares MBS ETF: 4,310,047 shares worth $405M.
- Barclays added most to NVIDIA in Q2 2025, an estimated $1.6B increase.
- Barclays's biggest Q2 2025 reduction was Honeywell, cutting an estimated $1.54B.
- Barclays fully exited Berry Global Group, Inc. in Q2 2025, selling an estimated $173M.
- Barclays's ten largest holdings make up 43% of its $436B portfolio in Q2 2025.
- Barclays opened 461 new positions and closed 463 in Q2 2025.
- Barclays's portfolio value rose 24% quarter-over-quarter to $436B.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.